Palvella Therapeutics, Inc. (NASDAQ:PVLA)
| Market Cap | $2.24B+90.3% |
| Revenue (ttm) | $0 |
| Net Income | -$74.99M-127.6% |
| EPS | -$5.50+14.7% |
| Shares Out | 14.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,742 |
| Open | $164.16 |
| Previous Close | $163.94 |
| Day's Range | $152.13 - $165.16 |
| 52-Week Range | $72.22 - $179.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $230.20(+50.28%) |
| Earnings Date | Mar 30, 2027 |
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating PVLA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 30, 2027Earnings report
$PVLA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PVLA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PVLA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PVLA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PVLA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PVLA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PVLA
| XBIState Street SPDR S&P Biotech ETF | $62.72M |
| VTIVanguard Morningstar Total Stock Market ETF | $53.86M |
| IWMiShares Russell 2000 ETF | $50.49M |
| VXFVanguard Extended Market ETF | $19.08M |
| IWOiShares Russell 2000 Growth ETF | $18.48M |
| SCHASchwab U.S. Small-Cap ETF | $10.06M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PVLA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Oppenheimer price target raise and FDA priority review offset by Q3 net loss widening; mixed but moderately positive fundamentals.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 2.29% |
| SBIO | ALPS Medical Breakthroughs ETF | 1.44% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.38% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.11% |
| TDNA | T. Rowe Price Biotech ETF | 1.04% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.92% |
| XBI | State Street SPDR S&P Biotech ETF | 0.58% |
| MEDI | Harbor Health Care ETF (MEDI) | 0.55% |
| RUSC | Russell Investments Exchange Traded Funds - Russell Investments US Small Cap Equity ETF | 0.31% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 0.28% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.14% |
| IWO | iShares Russell 2000 Growth ETF | 0.13% |
Weight is the stock’s share of each fund’s holdings.